Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) and BioNTech (NASDAQ:BNTX – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.
Institutional and Insider Ownership
15.5% of BioNTech shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Nurix Therapeutics and BioNTech”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nurix Therapeutics | $83.98 million | 29.51 | -$264.46 million | ($3.45) | -6.92 |
| BioNTech | $3.25 billion | 7.67 | -$1.29 billion | ($7.83) | -12.57 |
Nurix Therapeutics has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and price targets for Nurix Therapeutics and BioNTech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nurix Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
| BioNTech | 1 | 5 | 12 | 1 | 2.68 |
Nurix Therapeutics presently has a consensus target price of $34.21, indicating a potential upside of 43.28%. BioNTech has a consensus target price of $126.00, indicating a potential upside of 27.97%. Given Nurix Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Nurix Therapeutics is more favorable than BioNTech.
Risk and Volatility
Nurix Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.
Profitability
This table compares Nurix Therapeutics and BioNTech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nurix Therapeutics | -928.44% | -76.09% | -57.31% |
| BioNTech | -63.54% | -6.86% | -6.00% |
Summary
Nurix Therapeutics beats BioNTech on 8 of the 15 factors compared between the two stocks.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
About BioNTech
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
